Profile
Dr. Russell T.
Kawahata is Vice President-Pharmaceutical Science at NeurogesX, Inc.
Dr. Kawahata was previously employed as Vice President-Technical Development & Operations by InterMune, Inc., General Manager by Soltec Research Pty Ltd., Senior Director-Product Innovation by Connetics Corp., a Director-Process Development by Systemix, Inc., and a Director-Process Development by XOMA Corp.
He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from the University of California, Davis.
Former positions of Russell T. Kawahata
Companies | Position | End |
---|---|---|
INTERMUNE INC | Corporate Officer/Principal | 2006-12-31 |
Stiefel Research Australia Pty Ltd.
Stiefel Research Australia Pty Ltd. BiotechnologyHealth Technology Part of GSK Plc, Stiefel Research Australia Pty Ltd. is an Australian company that develops delivery systems for new dermatology products. The company is based in Rowville, Australia. Stiefel Research Australia was acquired by Connetics Corp. from FH Faulding & Co. Ltd. on April 23, 2001 for $15.93 million. | Corporate Officer/Principal | 2001-12-31 |
Connetics Corp.
Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | 2000-12-31 |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Corporate Officer/Principal | - |
XOMA CORPORATION | Corporate Officer/Principal | - |
Training of Russell T. Kawahata
University of California, Davis | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
XOMA CORPORATION | Health Technology |
Private companies | 5 |
---|---|
NeurogesX, Inc.
NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA. | Health Technology |
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Connetics Corp.
Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Stiefel Research Australia Pty Ltd.
Stiefel Research Australia Pty Ltd. BiotechnologyHealth Technology Part of GSK Plc, Stiefel Research Australia Pty Ltd. is an Australian company that develops delivery systems for new dermatology products. The company is based in Rowville, Australia. Stiefel Research Australia was acquired by Connetics Corp. from FH Faulding & Co. Ltd. on April 23, 2001 for $15.93 million. | Health Technology |
Systemix, Inc.
Systemix, Inc. Medical/Nursing ServicesHealth Services Systemix, Inc. develops cell-based gene therapies for diseases. The company is based in Palo Alto, CA. The company was founded by Irving L. Weissman, Leroy E. Hood. Systemix was acquired by Novartis AG on February 14, 1997 for $75.90 million. | Health Services |
- Stock Market
- Insiders
- Russell T. Kawahata